156 related articles for article (PubMed ID: 23203162)
1. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline.
Grundman M; Pontecorvo MJ; Salloway SP; Doraiswamy PM; Fleisher AS; Sadowsky CH; Nair AK; Siderowf A; Lu M; Arora AK; Agbulos A; Flitter ML; Krautkramer MJ; Sarsour K; Skovronsky DM; Mintun MA;
Alzheimer Dis Assoc Disord; 2013; 27(1):4-15. PubMed ID: 23203162
[TBL] [Abstract][Full Text] [Related]
2. Impact of ¹⁸F-florbetapir PET imaging of β-amyloid neuritic plaque density on clinical decision-making.
Zannas AS; Doraiswamy PM; Shpanskaya KS; Murphy KR; Petrella JR; Burke JR; Wong TZ
Neurocase; 2014 Aug; 20(4):466-73. PubMed ID: 23672654
[TBL] [Abstract][Full Text] [Related]
3. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study.
Boccardi M; Altomare D; Ferrari C; Festari C; Guerra UP; Paghera B; Pizzocaro C; Lussignoli G; Geroldi C; Zanetti O; Cotelli MS; Turla M; Borroni B; Rozzini L; Mirabile D; Defanti C; Gennuso M; Prelle A; Gentile S; Morandi A; Vollaro S; Volta GD; Bianchetti A; Conti MZ; Cappuccio M; Carbone P; Bellandi D; Abruzzi L; Bettoni L; Villani D; Raimondi MC; Lanari A; Ciccone A; Facchi E; Di Fazio I; Rozzini R; Boffelli S; Manzoni L; Salvi GP; Cavaliere S; Belotti G; Avanzi S; Pasqualetti P; Muscio C; Padovani A; Frisoni GB;
JAMA Neurol; 2016 Dec; 73(12):1417-1424. PubMed ID: 27802513
[TBL] [Abstract][Full Text] [Related]
5. Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.
Cortes-Blanco A; Prieto-Yerro C; Martinez-Lazaro R; Zamora J; Jiménez-Huete A; Haberkamp M; Pohly J; Enzmann H; Zinserling J; Strassmann V; Broich K
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S395-9. PubMed ID: 24418060
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective.
Hornberger J; Michalopoulos S; Dai M; Andrade P; Dilla T; Happich M
J Ment Health Policy Econ; 2015 Jun; 18(2):63-73. PubMed ID: 26231002
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Florbetapir PET Imaging in Changing Patient Management.
Pontecorvo MJ; Siderowf A; Dubois B; Doraiswamy PM; Frisoni GB; Grundman M; Nobili F; Sadowsky CH; Salloway S; Arora AK; Chevrette A; Deberdt W; Dell'Agnello G; Flitter M; Galante N; Lowrey MJ; Lu M; McGeehan A; Devous MD; Mintun MA
Dement Geriatr Cogn Disord; 2017; 44(3-4):129-143. PubMed ID: 28787712
[TBL] [Abstract][Full Text] [Related]
8. Current status of PET-imaging probes of β-amyloid plaques.
Koo J; Byun Y
Arch Pharm Res; 2013 Oct; 36(10):1178-84. PubMed ID: 23812777
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of amyloid PET imaging with (18)F-florbetapir: a retrospective study of 100 patients.
Carswell CJ; Win Z; Muckle K; Kennedy A; Waldman A; Dawe G; Barwick TD; Khan S; Malhotra PA; Perry RJ
J Neurol Neurosurg Psychiatry; 2018 Mar; 89(3):294-299. PubMed ID: 29018162
[TBL] [Abstract][Full Text] [Related]
10. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
11. Brain amyloid imaging--FDA approval of florbetapir F18 injection.
Yang L; Rieves D; Ganley C
N Engl J Med; 2012 Sep; 367(10):885-7. PubMed ID: 22931256
[No Abstract] [Full Text] [Related]
12. A consecutive case series experience with [18 F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition.
Mitsis EM; Bender HA; Kostakoglu L; Machac J; Martin J; Woehr JL; Sewell MC; Aloysi A; Goldstein MA; Li C; Sano M; Gandy S
Mol Neurodegener; 2014 Feb; 9():10. PubMed ID: 24484858
[TBL] [Abstract][Full Text] [Related]
13. Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial.
Sevigny J; Suhy J; Chiao P; Chen T; Klein G; Purcell D; Oh J; Verma A; Sampat M; Barakos J
Alzheimer Dis Assoc Disord; 2016; 30(1):1-7. PubMed ID: 26885819
[TBL] [Abstract][Full Text] [Related]
14. Florbetapir F 18 for brain imaging of β-amyloid plaques.
Romano M; Buratti E
Drugs Today (Barc); 2013 Mar; 49(3):181-93. PubMed ID: 23527322
[TBL] [Abstract][Full Text] [Related]
15. Theoretical impact of Florbetapir (18F) amyloid imaging on diagnosis of alzheimer dementia and detection of preclinical cortical amyloid.
Beach TG; Schneider JA; Sue LI; Serrano G; Dugger BN; Monsell SE; Kukull W
J Neuropathol Exp Neurol; 2014 Oct; 73(10):948-53. PubMed ID: 25192053
[TBL] [Abstract][Full Text] [Related]
16. Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria.
Grundman M; Johnson KA; Lu M; Siderowf A; Dell'Agnello G; Arora AK; Skovronsky DM; Mintun MA; Pontecorvo MJ;
Dement Geriatr Cogn Disord; 2016; 41(1-2):80-92. PubMed ID: 26745445
[TBL] [Abstract][Full Text] [Related]
17. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
Joshi AD; Pontecorvo MJ; Clark CM; Carpenter AP; Jennings DL; Sadowsky CH; Adler LP; Kovnat KD; Seibyl JP; Arora A; Saha K; Burns JD; Lowrey MJ; Mintun MA; Skovronsky DM;
J Nucl Med; 2012 Mar; 53(3):378-84. PubMed ID: 22331215
[TBL] [Abstract][Full Text] [Related]
18. Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury.
Mitsis EM; Riggio S; Kostakoglu L; Dickstein DL; Machac J; Delman B; Goldstein M; Jennings D; D'Antonio E; Martin J; Naidich TP; Aloysi A; Fernandez C; Seibyl J; DeKosky ST; Elder GA; Marek K; Gordon W; Hof PR; Sano M; Gandy S
Transl Psychiatry; 2014 Sep; 4(9):e441. PubMed ID: 25226550
[TBL] [Abstract][Full Text] [Related]
19. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.
Okamura N; Yanai K
IDrugs; 2010 Dec; 13(12):890-9. PubMed ID: 21154149
[TBL] [Abstract][Full Text] [Related]
20. Beta amyloid imaging with positron emission tomography (PET) for evaluation of suspected Alzheimer's disease or other causes of cognitive decline.
Technol Eval Cent Assess Program Exec Summ; 2013 Feb; 27(5):1-4. PubMed ID: 23589929
[No Abstract] [Full Text] [Related]
[Next] [New Search]
